StreetInsider.com News Articles

Immucell Corp (ICCC) Reports Q2 EPS of $0.20

Thu, 13 Aug 2026 16:30:29 -0400

Immucell Corp (NASDAQ: ICCC) reported Q2 EPS of $0.20. Revenue for the quarter came in at $7.18 million.

For earnings history and earnings-related data on Immucell Corp (ICCC) click here.

Form 10-Q IMMUCELL CORP /DE/ For: Jun 30

Thu, 13 Aug 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260813/26921046.html

Form 10-Q IMMUCELL CORP /DE/ For: Jun 30

Thu, 13 Aug 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260813/26921046.html

Form 8-K IMMUCELL CORP /DE/ For: Aug 13

Thu, 13 Aug 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260813/26920984.html

Form 8-K IMMUCELL CORP /DE/ For: Aug 13

Thu, 13 Aug 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260813/26920984.html

ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2026

Thu, 13 Aug 2026 16:05:00 -0400

PORTLAND, Maine, Aug. 13, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops, manufactures and markets products to improve calf health and productivity, today announced its unaudited financial results for the quarter ended June 30, 2026.

Management’s Discussion:

“Today we are reporting net income of $1.8 million for the second quarter of 2026,” commented Timothy C. Fiori, Chief Financial Officer of ImmuCell. “Revenue grew 11.5% to $7.2 million in the second quarter of 2026, which is a strong positive market signal in the face of

ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2026

Thu, 13 Aug 2026 16:05:00 -0400

Management’s Discussion:

ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2026

Thu, 13 Aug 2026 16:05:00 -0400

Management’s Discussion:

ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2026

Thu, 13 Aug 2026 16:05:00 -0400

Management’s Discussion:

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2026

Thu, 06 Aug 2026 16:05:00 -0400

PORTLAND, Maine, Aug. 06, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops, manufactures and markets products to improve calf health and productivity, expects to report unaudited financial results for the quarter ended June 30, 2026 after the market closes on Thursday, August 13, 2026.

The Company is planning to host a conference call and webcast on August 14, 2026, at 9:00 AM ET to review the unaudited financial results. Interested parties may access the conference call by dialing (844) 855-9502 (toll free) or (412) 317-5499 (international).

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2026

Thu, 06 Aug 2026 16:05:00 -0400

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2026

Thu, 06 Aug 2026 16:05:00 -0400

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2026

Thu, 06 Aug 2026 16:05:00 -0400

Form 8-K IMMUCELL CORP /DE/ For: Jul 09

Thu, 09 Jul 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260709/26753287.html

Form 8-K IMMUCELL CORP /DE/ For: Jul 09

Thu, 09 Jul 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260709/26753287.html

ImmuCell reports 11.5% sales rise in Q2 2026, 20.9% gain for first half

Thu, 09 Jul 2026 16:06:06 -0400

ImmuCell Corporation (Nasdaq: ICCC) reported preliminary, unaudited total product sales of $7.2 million for the three months ended June 30, 2026, an 11.5% increase from $6.4 million in the same period of 2025, according to a company press release.

Domestic sales drove the quarterly result, rising 27.7% to $6.2 million from $4.9 million a year earlier. International sales fell 38.9% to $1.0 million from $1.6 million in the prior-year quarter.

By product, Tri-Shield First Defense sales reached $4.9 million in Q2 2026, up 8.3% from $4.5 million, while Dual-Force and other sales rose 19.1% to $2.3 million from $1.9 million.

For the six

ImmuCell reports 11.5% sales rise in Q2 2026, 20.9% gain for first half

Thu, 09 Jul 2026 16:06:06 -0400

Domestic sales drove the quarterly result, rising 27.7% to $6.2 million from $4.9 million a year earlier. International sales fell 38.9% to $1.0 million from $1.6 million in the prior-year quarter.

By product, Tri-Shield First Defense sales reached $4.9 million in Q2 2026, up 8.3% from $4.5 million, while Dual-Force and other sales rose 19.1% to $2.3 million from $1.9 million.

For the six

ImmuCell Announces a 12% Increase in Product Sales in Q2 of 2026 and a 21% Increase in the First Six Months of 2026, Based on Preliminary, Unaudited Sales Results

Thu, 09 Jul 2026 16:05:00 -0400

PORTLAND, Maine, July 09, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops, manufactures and markets products to improve calf health and productivity, today announced preliminary, unaudited sales results for the second quarter of 2026.

“Total sales for the three months ended June 30, 2026 were $7.2 million, an 11.5% increase compared to the three months ended June 30, 2025, driven by a 27.7% increase in domestic sales compared to 2025,” said Timothy Fiori, Chief Financial Officer of ImmuCell. “Our growth in the second quarter is particularly significant given

ImmuCell Announces a 12% Increase in Product Sales in Q2 of 2026 and a 21% Increase in the First Six Months of 2026, Based on Preliminary, Unaudited Sales Results

Thu, 09 Jul 2026 16:05:00 -0400

ImmuCell Announces a 12% Increase in Product Sales in Q2 of 2026 and a 21% Increase in the First Six Months of 2026, Based on Preliminary, Unaudited Sales Results

Thu, 09 Jul 2026 16:05:00 -0400

ImmuCell Announces a 12% Increase in Product Sales in Q2 of 2026 and a 21% Increase in the First Six Months of 2026, Based on Preliminary, Unaudited Sales Results

Thu, 09 Jul 2026 16:05:00 -0400

Form 4 IMMUCELL CORP /DE/ For: Jun 18 Filed by: te Boekhorst Paul Francis Olivier

Mon, 22 Jun 2026 08:34:00 -0400

si-local-file:///var/storage/secattach/20260622/26670463.html

Form 4 IMMUCELL CORP /DE/ For: Jun 18 Filed by: te Boekhorst Paul Francis Olivier

Mon, 22 Jun 2026 08:34:00 -0400

si-local-file:///var/storage/secattach/20260622/26670463.html

Form 8-K IMMUCELL CORP /DE/ For: Jun 11

Wed, 17 Jun 2026 14:19:00 -0400

si-local-file:///var/storage/secattach/20260617/26659308.html

Form 8-K IMMUCELL CORP /DE/ For: Jun 11

Wed, 17 Jun 2026 14:19:00 -0400

si-local-file:///var/storage/secattach/20260617/26659308.html